The Advanced Research Projects Agency for Health (ARPA-H) recently launched the Computational ADME-Tox and Physiology Analysis for Safer Therapeutics (CATALYST) program, which aims to revolutionize preclinical drug safety prediction by developing human-based models that accurately estimate toxicity and safety profiles for drug candidates. ARPA-H Program Manager Andy Kilianski, Ph.D., hosted an information session to provide potential performers with an overview of CATALYST, the goals of the program, technical areas of focus, and upcoming deadlines.